Supplementary Table 6．Impact of prevalence of ≥F2, ≥F3 and F4 on PPV and NPV of LSM, and for the cutoff for Se=0.90, cutoff for Youden index and cutoff for Sp=0.90

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Prevalence | Justification | Cutoff for Se=0.90 | Cutoff for Youden index | Cutoff for Sp=0.90 |
| Diagnostic of ≥F2 |  |  | Cutoff=5.3kPa | Cutoff= 9.4kPa | Cutoff=13.3kPa |
|  | 0.61 | Actual prevalence in our cohort | PPV=64%NPV=71% | PPV=83%NPV=56% | PPV=85%NPV=47% |
|  | 0.40 | Estimated prevalence in diabetic clinic [21] | PPV=44%NPV=80% | PPV=68%NPV=74% | PPV=71%NPV=67% |
|  | 0.07 | Estimated prevalence in general population [23] | PPV=8%NPV=97% | PPV=19%NPV=96% | PPV=22%NPV=95% |
| Diagnostic of ≥F3 |  |  | Cutoff=6.1kPa | Cutoff=9.4 kPa | Cutoff=15kPa |
|  | 0.36 | Actual prevalence in our cohort | PPV=40%NPV=80% | PPV=58% NPV=80% | PPV=69%NPV=73% |
|  | 0.18 | Estimated prevalence in diabetic clinic [21] | PPV=21%NPV=91% | PPV=35%NPV=91% | PPV=47%NPV=87% |
|  | 0.02 | Estimated prevalence in general population [24] | PPV=2%NPV=99% | PPV=5%NPV=99% | PPV=8%NPV=99% |
| Diagnostic of F4 |  |  | Cutoff=11kPa | Cutoff=11kPa | Cutoff=21.4kPa |
|  | 0.04 | Actual prevalence in our cohort | PPV=9%NPV=99% | PPV=9%NPV=99% | PPV=13%NPV=98% |
|  | 0.03 | Estimated prevalence in patients at risk of liver disease [25] | PPV=8%NPV=99% | PPV=8%NPV=99% | PPV=11%NPV=98% |
|  | 0.01 | Estimated prevalence in general population [25] | PPV=3%NPV=99.7% | PPV=3%NPV=99.7% | PPV=4%NPV=99.3% |